002030 达安基因
已收盘 09-11 15:00:00
资讯
新帖
简况
达安基因获得发明专利授权：“重组抗坏血酸氧化酶的制备方法”
证券之星 · 03:28
达安基因获得发明专利授权：“重组抗坏血酸氧化酶的制备方法”
达安基因(002030)8月31日股东户数13.2万户，较上期减少0.75%
证券之星 · 09-09
达安基因(002030)8月31日股东户数13.2万户，较上期减少0.75%
达安基因（002030）披露2026年半年度报告，8月31日股价下跌3.02%
证券之星 · 08-31
达安基因（002030）披露2026年半年度报告，8月31日股价下跌3.02%
达安基因（002030）2026年中报简析：亏损收窄，盈利能力上升
证券之星 · 08-30
达安基因（002030）2026年中报简析：亏损收窄，盈利能力上升
达安基因(002030)7月31日股东户数13.3万户，较上期减少1.53%
证券之星 · 08-29
达安基因(002030)7月31日股东户数13.3万户，较上期减少1.53%
图解达安基因中报：第二季度单季净利润同比增长90.54%
证券之星 · 08-29
图解达安基因中报：第二季度单季净利润同比增长90.54%
达安基因：公司目前已围绕市场洞察、研发注册、质量管控推进AI工具落地
证券之星 · 08-26
达安基因：公司目前已围绕市场洞察、研发注册、质量管控推进AI工具落地
达安基因(002030)7月31日股东户数13.3万户，较上期减少1.48%
证券之星 · 08-26
达安基因(002030)7月31日股东户数13.3万户，较上期减少1.48%
达安基因：截至2026年7月31日，公司股东总户数约为13万3千户
证券之星 · 08-26
达安基因：截至2026年7月31日，公司股东总户数约为13万3千户
达安基因：间接控股股东变更后将继续保持业务、资产、人员、财务等方面的独立性
证券之星 · 08-26
达安基因：间接控股股东变更后将继续保持业务、资产、人员、财务等方面的独立性
【投融资动态】中达合成出资设立融资，投资方为达安基因
证券之星 · 08-24
【投融资动态】中达合成出资设立融资，投资方为达安基因
达安基因：持续跟踪埃博拉相关公共卫生防控形势
证券之星 · 08-19
达安基因：持续跟踪埃博拉相关公共卫生防控形势
股市必读：达安基因新发布《关于取得一个医疗器械注册证的提示性公告》
证券之星 · 08-19
股市必读：达安基因新发布《关于取得一个医疗器械注册证的提示性公告》
达安基因最新公告：取得人副流感病毒核酸检测试剂盒医疗器械注册证
证券之星 · 08-18
达安基因最新公告：取得人副流感病毒核酸检测试剂盒医疗器械注册证
股市必读：达安基因新发布《关于公司控股股东股权转让完成工商变更登记暨间接控股股东变更的公告》
证券之星 · 08-17
股市必读：达安基因新发布《关于公司控股股东股权转让完成工商变更登记暨间接控股股东变更的公告》
股市必读：达安基因(002030)股东户数13.3万户，较上期减少1.48%
证券之星 · 08-14
股市必读：达安基因(002030)股东户数13.3万户，较上期减少1.48%
达安基因(002030)7月31日股东户数13.3万户，较上期减少1.48%
证券之星 · 08-11
达安基因(002030)7月31日股东户数13.3万户，较上期减少1.48%
达安基因：截至2026年7月31日，公司股东总户数约为13万3千户
证券之星 · 08-11
达安基因：截至2026年7月31日，公司股东总户数约为13万3千户
股市必读：达安基因新发布《关于下属子公司取得一个医疗器械注册证的提示性公告》
证券之星 · 08-10
股市必读：达安基因新发布《关于下属子公司取得一个医疗器械注册证的提示性公告》
达安基因（002030）披露下属子公司取得甲胎蛋白测定试剂盒医疗器械注册证，8月6日股价上涨0.36%
证券之星 · 08-06
达安基因（002030）披露下属子公司取得甲胎蛋白测定试剂盒医疗器械注册证，8月6日股价上涨0.36%
加载更多
公司概况
公司名称：
广州达安基因股份有限公司
所属行业：
医药制造业
上市日期：
2004-08-09
主营业务：
广州达安基因股份有限公司的主营业务是体外诊断试剂、仪器和配套耗材的研发、生产与销售。公司的主要产品是试剂、仪器设备、配套耗材。公司为全国首批体外诊断高新技术企业。
发行价格：
7.30
{"stockData":{"symbol":"002030","market":"SZ","secType":"STK","nameCN":"达安基因","latestPrice":5.28,"timestamp":1789110237000,"preClose":5.41,"halted":0,"volume":16345169,"delay":0,"changeRate":-0.024,"floatShares":1403000000,"shares":1403000000,"eps":-0.4864,"marketStatus":"已收盘","change":-0.13,"latestTime":"09-11 15:00:00","open":5.36,"high":5.37,"low":5.24,"amount":86347900,"amplitude":0.024,"askPrice":5.28,"askSize":1042,"bidPrice":5.27,"bidSize":1985,"shortable":0,"etf":0,"ttmEps":-0.4864,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1789349400000},"marketStatusCode":5,"adr":0,"adjPreClose":5.41,"symbolType":"stock","openAndCloseTimeList":[[1789090200000,1789097400000],[1789102800000,1789110000000]],"highLimit":5.95,"lowLimit":4.87,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1403446032,"isCdr":false,"pbRate":1.08,"roa":"--","roe":"--","epsLYR":-0.53,"committee":0.539897,"marketValue":7410000000,"turnoverRate":0.0116,"status":1,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2026-09-14。","floatMarketCap":7410000000},"requestUrl":"/m/hq/s/002030","defaultTab":"news","newsList":[{"id":"2667150015","title":"达安基因获得发明专利授权：“重组抗坏血酸氧化酶的制备方法”","url":"https://stock-news.laohu8.com/highlight/detail?id=2667150015","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667150015?lang=zh_cn&edition=full","pubTime":"2026-09-13 03:28","pubTimestamp":1789241321,"startTime":"0","endTime":"0","summary":"证券之星消息，根据天眼查APP数据显示达安基因新获得一项发明专利授权，专利名为“重组抗坏血酸氧化酶的制备方法”，专利申请号为CN202311102586.8，授权日为2026年9月11日。今年以来达安基因新获得专利授权24个，较去年同期增加了166.67%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091300001215.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002030","BK0239","BK0168","BK0188","BK0159","BK0042","BK0028","BK0122","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666589736","title":"达安基因(002030)8月31日股东户数13.2万户，较上期减少0.75%","url":"https://stock-news.laohu8.com/highlight/detail?id=2666589736","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666589736?lang=zh_cn&edition=full","pubTime":"2026-09-09 17:27","pubTimestamp":1788946023,"startTime":"0","endTime":"0","summary":"证券之星消息，近日达安基因披露，截至2026年8月31日公司股东户数为13.2万户，较7月31日减少1000.0户，减幅为0.75%。在医疗器械行业个股中，达安基因股东户数高于行业平均水平，截至8月31日，医疗器械行业平均股东户数为2.08万户。从股价来看，2026年7月31日至2026年8月31日，达安基因区间涨幅为0.18%，在此期间股东户数减少1000.0户，减幅为0.75%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090900029316.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","002030","BK0159","BK0168","BK0122","BK0046","BK0042","BK0239","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663071535","title":"达安基因（002030）披露2026年半年度报告，8月31日股价下跌3.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663071535","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663071535?lang=zh_cn&edition=full","pubTime":"2026-08-31 17:50","pubTimestamp":1788169858,"startTime":"0","endTime":"0","summary":"截至2026年8月31日收盘，达安基因报收于5.46元，较前一交易日下跌3.02%，最新总市值为76.63亿元。该股当日开盘5.58元，最高5.6元，最低5.44元，成交额达1.13亿元，换手率为1.46%。近日，广州达安基因股份有限公司发布2026年半年度报告摘要。报告期内，公司营业收入为327,825,993.97元，较上年同期的338,574,032.79元下降3.17%。归属于上市公司股东的净利润为-120,386,063.78元，较上年同期的-182,160,988.30元上升33.91%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083100025281.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0122","BK0168","BK0028","BK0159","BK0188","BK0046","BK0042","002030","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663048266","title":"达安基因（002030）2026年中报简析：亏损收窄，盈利能力上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2663048266","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663048266?lang=zh_cn&edition=full","pubTime":"2026-08-30 06:22","pubTimestamp":1788042170,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期达安基因发布2026年中报。截至本报告期末，公司营业总收入3.28亿元，同比下降3.17%，归母净利润-1.2亿元，同比上升33.91%。本报告期达安基因盈利能力上升，毛利率同比增幅2.35%，净利率同比增幅32.39%。本文数据来源于达安基因2026年中报，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083000002666.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0159","BK0168","BK0122","BK0028","BK0188","002030","BK0046","BK0239","BK0042"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663628012","title":"达安基因(002030)7月31日股东户数13.3万户，较上期减少1.53%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663628012","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663628012?lang=zh_cn&edition=full","pubTime":"2026-08-29 17:13","pubTimestamp":1787994805,"startTime":"0","endTime":"0","summary":"证券之星消息，近日达安基因披露，截至2026年7月31日公司股东户数为13.3万户，较6月30日减少2070.0户，减幅为1.53%。在医疗器械行业个股中，达安基因股东户数高于行业平均水平，截至7月31日，医疗器械行业平均股东户数为2.09万户。从股价来看，2026年6月30日至2026年7月31日，达安基因区间涨幅为8.13%，在此期间股东户数减少2070.0户，减幅为1.53%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082900023490.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0122","BK0188","BK0028","BK0159","BK0042","002030","BK0239","BK0046","BK0168"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663179018","title":"图解达安基因中报：第二季度单季净利润同比增长90.54%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663179018","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663179018?lang=zh_cn&edition=full","pubTime":"2026-08-29 02:27","pubTimestamp":1787941661,"startTime":"0","endTime":"0","summary":"证券之星消息，达安基因2026年中报显示，上半年度公司主营收入3.28亿元，同比下降3.17%；归母净利润-1.2亿元，同比上升33.91%；扣非净利润-5185.05万元，同比上升80.4%；其中2026年第二季度，公司单季度主营收入1.78亿元，同比上升5.28%；单季度归母净利润-2223.13万元，同比上升90.54%；单季度扣非净利润-803.66万元，同比上升95.15%；负债率12.57%，投资收益2102.66万元，财务费用-627.08万元，毛利率33.81%。财报数据概要请见下图:本文数据来源于达安基因2026年中报，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082900006075.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002030"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662714864","title":"达安基因：公司目前已围绕市场洞察、研发注册、质量管控推进AI工具落地","url":"https://stock-news.laohu8.com/highlight/detail?id=2662714864","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662714864?lang=zh_cn&edition=full","pubTime":"2026-08-26 20:51","pubTimestamp":1787748676,"startTime":"0","endTime":"0","summary":"证券之星消息，达安基因(002030)08月25日在投资者关系平台上答复投资者关心的问题。投资者提问：你好，董秘，AI技术越来越多行业使用，对贵公司有哪些积极影响？达安基因回复：投资者您好，感谢您对达安基因的关注。公司目前已围绕市场洞察、研发注册、质量管控推进AI工具落地。现阶段相关应用尚处于初步融合阶段，后续公司将持续探索AI与IVD业务场景的结合，力争为经营发展提供助力。谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082600048660.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","002030","BK0159","BK0168","BK0122","BK0046","BK0042","BK0239","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662705794","title":"达安基因(002030)7月31日股东户数13.3万户，较上期减少1.48%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662705794","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662705794?lang=zh_cn&edition=full","pubTime":"2026-08-26 17:40","pubTimestamp":1787737254,"startTime":"0","endTime":"0","summary":"证券之星消息，近日达安基因披露，截至2026年7月31日公司股东户数为13.3万户，较6月30日减少2000.0户，减幅为1.48%。在医疗器械行业个股中，达安基因股东户数高于行业平均水平，截至7月31日，医疗器械行业平均股东户数为2.13万户。从股价来看，2026年6月30日至2026年7月31日，达安基因区间涨幅为8.13%，在此期间股东户数减少2000.0户，减幅为1.48%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082600039775.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0159","BK0188","BK0046","BK0168","BK0028","BK0239","002030","BK0122","BK0042"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662765160","title":"达安基因：截至2026年7月31日，公司股东总户数约为13万3千户","url":"https://stock-news.laohu8.com/highlight/detail?id=2662765160","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662765160?lang=zh_cn&edition=full","pubTime":"2026-08-26 08:57","pubTimestamp":1787705826,"startTime":"0","endTime":"0","summary":"证券之星消息，达安基因(002030)08月25日在投资者关系平台上答复投资者关心的问题。投资者提问：请问8月20日股东人数是多少？谢谢达安基因回复：投资者您好，感谢您对达安基因的关注。公司仅提供每月月末股东人数，截至2026年7月31日，公司股东总户数约为13万3千户。谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：沈彬","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082600015492.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0159","BK0042","BK0122","BK0028","BK0239","BK0168","BK0046","BK0188","002030"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662176516","title":"达安基因：间接控股股东变更后将继续保持业务、资产、人员、财务等方面的独立性","url":"https://stock-news.laohu8.com/highlight/detail?id=2662176516","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662176516?lang=zh_cn&edition=full","pubTime":"2026-08-26 08:54","pubTimestamp":1787705654,"startTime":"0","endTime":"0","summary":"证券之星消息，达安基因(002030)08月25日在投资者关系平台上答复投资者关心的问题。投资者提问：你好，董秘，广药成为贵公司控股股东，是否有意打造另外一个广药？达安基因回复：投资者您好，感谢您对达安基因的关注。间接控股股东变更后，公司将继续保持业务、资产、人员、财务等方面的独立性，持续聚焦体外诊断主业，依法合规经营。谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：陈思雨","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082600015273.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0159","BK0168","BK0239","BK0042","BK0188","BK0046","002030","BK0122","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661753672","title":"【投融资动态】中达合成出资设立融资，投资方为达安基因","url":"https://stock-news.laohu8.com/highlight/detail?id=2661753672","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661753672?lang=zh_cn&edition=full","pubTime":"2026-08-24 19:26","pubTimestamp":1787570763,"startTime":"0","endTime":"0","summary":"证券之星消息，根据天眼查APP于8月18日公布的信息整理，中达合成生物科技（广州）有限公司出资设立融资，融资额未披露，参与投资的机构包括达安基因。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082400031083.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0159","BK0028","BK0188","BK0239","002030","BK0046","BK0042","BK0168","BK0122"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660413997","title":"达安基因：持续跟踪埃博拉相关公共卫生防控形势","url":"https://stock-news.laohu8.com/highlight/detail?id=2660413997","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660413997?lang=zh_cn&edition=full","pubTime":"2026-08-19 08:33","pubTimestamp":1787099585,"startTime":"0","endTime":"0","summary":"证券之星消息，达安基因(002030)08月18日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘你好，请问公司现在是否有关注埃博拉疫情，对扎伊尔型和BDBV试剂盒是否有推进世卫认证的计划？达安基因回复：投资者您好，感谢您对达安基因的关注。公司持续跟踪埃博拉相关公共卫生防控形势，公司将结合市场实际需求动态评估相关申报计划。谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：沈彬","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081900007401.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0168","BK0122","002030","BK0188","BK0239","BK0159","BK0046","BK0028","BK0042"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660144499","title":"股市必读：达安基因新发布《关于取得一个医疗器械注册证的提示性公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2660144499","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660144499?lang=zh_cn&edition=full","pubTime":"2026-08-19 01:34","pubTimestamp":1787074450,"startTime":"0","endTime":"0","summary":"截至2026年8月18日收盘，达安基因报收于5.62元，下跌1.75%，换手率1.73%，成交量24.22万手，成交额1.38亿元。公司公告汇总关于取得一个医疗器械注册证的提示性公告广州达安基因股份有限公司近日取得国家药品监督管理局颁发的医疗器械注册证，产品名称为人副流感病毒核酸检测试剂盒，注册证编号国械注准20263401731，有效期至2031年8月16日。该产品用于定性检测人口咽拭子中的人副流感病毒RNA，包括Ⅰ型、Ⅱ型、Ⅲ型和Ⅳ型，检测结果不区分型别。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081900001473.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0122","BK0168","BK0159","BK0042","BK0239","BK0046","002030","BK0028","159883","BK0188","09996","BK1100","BK1574","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660466399","title":"达安基因最新公告：取得人副流感病毒核酸检测试剂盒医疗器械注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2660466399","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660466399?lang=zh_cn&edition=full","pubTime":"2026-08-18 17:40","pubTimestamp":1787046031,"startTime":"0","endTime":"0","summary":"达安基因(002030.SZ)公告称，公司取得国家药品监督管理局颁发的医疗器械注册证一个，为人副流感病毒核酸检测试剂盒(荧光PCR法)，注册证编号为国械注准20263401731，有效期至2031年8月16日。该产品用于定性检测人口咽拭子中人副流感病毒RNA，检测结果不区分病毒型别。此次注册证的取得丰富了公司产品组合，拓宽了应用领域，但产品尚处市场开发阶段，需求存在不确定性，提醒投资者注意风险。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081800031469.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","BK0188","BK0028","002030","BK0159","BK0042","BK0168","BK0046","BK1100","09996","159883","BK1583","BK0122","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660170362","title":"股市必读：达安基因新发布《关于公司控股股东股权转让完成工商变更登记暨间接控股股东变更的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2660170362","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660170362?lang=zh_cn&edition=full","pubTime":"2026-08-17 01:32","pubTimestamp":1786901531,"startTime":"0","endTime":"0","summary":"公司公告汇总关于公司控股股东股权转让完成工商变更登记暨间接控股股东变更的公告2026年8月13日，广州广永科技发展有限公司完成股东变更登记，股东由广州金控集团变更为广州广药资本有限公司。达安基因控股股东仍为广永科技，间接控股股东变更为广药资本，实际控制人仍为广州市人民政府。股权转让部分已完成，但协议转让达安基因股份事项尚需深交所合规性确认及办理过户登记。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081700000550.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0168","BK0188","002030","BK0042","BK0046","BK0122","BK0028","BK0159"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659169460","title":"股市必读：达安基因(002030)股东户数13.3万户，较上期减少1.48%","url":"https://stock-news.laohu8.com/highlight/detail?id=2659169460","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659169460?lang=zh_cn&edition=full","pubTime":"2026-08-14 01:21","pubTimestamp":1786641678,"startTime":"0","endTime":"0","summary":"截至2026年8月13日收盘，达安基因报收于5.66元，上涨0.35%，换手率1.89%，成交量26.52万手，成交额1.5亿元。当日关注点交易信息汇总：8月13日主力资金净流入950.35万元，占总成交额6.33%。股本股东变化股东户数变动截至2026年7月31日，达安基因股东户数为13.3万户，较6月30日减少2000户，减幅1.48%；户均持股数量由1.04万股增至1.06万股，户均持股市值为5.75万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081400000912.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0122","BK0168","BK0028","BK0159","BK0188","BK0046","BK0042","002030","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658996145","title":"达安基因(002030)7月31日股东户数13.3万户，较上期减少1.48%","url":"https://stock-news.laohu8.com/highlight/detail?id=2658996145","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658996145?lang=zh_cn&edition=full","pubTime":"2026-08-11 17:29","pubTimestamp":1786440575,"startTime":"0","endTime":"0","summary":"证券之星消息，近日达安基因披露，截至2026年7月31日公司股东户数为13.3万户，较6月30日减少2000.0户，减幅为1.48%。在医疗器械行业个股中，达安基因股东户数高于行业平均水平，截至7月31日，医疗器械行业平均股东户数为2.14万户。从股价来看，2026年6月30日至2026年7月31日，达安基因区间涨幅为8.13%，在此期间股东户数减少2000.0户，减幅为1.48%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081100028019.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0159","BK0042","BK0028","BK0046","BK0188","002030","BK0122","BK0168"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658963252","title":"达安基因：截至2026年7月31日，公司股东总户数约为13万3千户","url":"https://stock-news.laohu8.com/highlight/detail?id=2658963252","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658963252?lang=zh_cn&edition=full","pubTime":"2026-08-11 09:15","pubTimestamp":1786410919,"startTime":"0","endTime":"0","summary":"证券之星消息，达安基因(002030)08月10日在投资者关系平台上答复投资者关心的问题。投资者提问：请问公司2026年7月31日A股股东人数是多少？谢谢达安基因回复：投资者您好，感谢您对达安基因的关注。截至2026年7月31日，公司股东总户数约为13万3千户。谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：沈彬","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081100007302.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0122","BK0159","BK0046","002030","BK0168","BK0042","BK0028","BK0188","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658608374","title":"股市必读：达安基因新发布《关于下属子公司取得一个医疗器械注册证的提示性公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2658608374","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658608374?lang=zh_cn&edition=full","pubTime":"2026-08-10 02:32","pubTimestamp":1786300333,"startTime":"0","endTime":"0","summary":"截至2026年8月7日收盘，达安基因报收于5.61元，上涨0.72%，换手率1.83%，成交量25.68万手，成交额1.42亿元。公司公告汇总关于下属子公司取得一个医疗器械注册证的提示性公告广州达安基因股份有限公司下属全资子公司广州达泰生物工程技术有限公司近日取得国家药品监督管理局颁发的医疗器械注册证，产品为甲胎蛋白测定试剂盒，注册证编号：国械注准20263401671，有效期至2031年8月3日。目前该产品尚处于市场开发阶段，市场需求存在不确定性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081000001091.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1100","09996","BK1574","BK0159","BK0188","BK0122","BK0168","BK0046","BK1583","BK0028","159883","BK0239","BK0042","002030"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657630045","title":"达安基因（002030）披露下属子公司取得甲胎蛋白测定试剂盒医疗器械注册证，8月6日股价上涨0.36%","url":"https://stock-news.laohu8.com/highlight/detail?id=2657630045","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657630045?lang=zh_cn&edition=full","pubTime":"2026-08-06 22:30","pubTimestamp":1786026636,"startTime":"0","endTime":"0","summary":"截至2026年8月6日收盘，达安基因报收于5.57元，较前一交易日上涨0.36%，最新总市值为78.17亿元。该股当日开盘5.68元，最高5.77元，最低5.52元，成交额达1.69亿元，换手率为2.15%。近日，广州达安基因股份有限公司下属全资子公司广州达泰生物工程技术有限公司取得国家药品监督管理局颁发的医疗器械注册证，产品为甲胎蛋白测定试剂盒，注册证编号：国械注准20263401671，有效期至2031年8月3日。目前该产品尚处于市场开发阶段，市场需求存在不确定性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080600040019.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1100","BK1574","BK0122","09996","BK0239","BK0028","BK0046","002030","159883","BK0188","BK0168","BK1583","BK0042","BK0159"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1789281131940,"stockEarnings":[{"period":"1week","weight":-0.0222},{"period":"1month","weight":-0.0638},{"period":"3month","weight":-0.0186},{"period":"6month","weight":-0.147},{"period":"1year","weight":-0.1902},{"period":"ytd","weight":-0.1141}],"compareEarnings":[{"period":"1week","weight":-0.0107},{"period":"1month","weight":-0.0148},{"period":"3month","weight":-0.0356},{"period":"6month","weight":-0.0506},{"period":"1year","weight":0.0033},{"period":"ytd","weight":-0.0203}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"广州达安基因股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"132000人(较上一季度减少0.75%)","perCapita":"41894股","listingDate":"2004-08-09","address":"广东省广州市黄埔区高新技术开发区科学城香山路19号","registeredCapital":"140344万元","survey":" 广州达安基因股份有限公司的主营业务是体外诊断试剂、仪器和配套耗材的研发、生产与销售。公司的主要产品是试剂、仪器设备、配套耗材。公司为全国首批体外诊断高新技术企业。","listedPrice":7.3},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"达安基因(002030)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供达安基因(002030)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"达安基因,002030,达安基因股票,达安基因股票老虎,达安基因股票老虎国际,达安基因行情,达安基因股票行情,达安基因股价,达安基因股市,达安基因股票价格,达安基因股票交易,达安基因股票购买,达安基因股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"达安基因(002030)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供达安基因(002030)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}